BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29487978)

  • 1. Defective HLA class I antigen processing machinery in cancer.
    Cai L; Michelakos T; Yamada T; Fan S; Wang X; Schwab JH; Ferrone CR; Ferrone S
    Cancer Immunol Immunother; 2018 Jun; 67(6):999-1009. PubMed ID: 29487978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
    Seliger B; Ferrone S
    Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
    Sabbatino F; Schwab JH; Ferrone S; Ferrone CR
    Clin Transpl; 2013; ():453-63. PubMed ID: 25095541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
    Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
    JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
    Maggs L; Sadagopan A; Moghaddam AS; Ferrone S
    Trends Cancer; 2021 Dec; 7(12):1089-1101. PubMed ID: 34489208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.
    Seliger B; Stoehr R; Handke D; Mueller A; Ferrone S; Wullich B; Tannapfel A; Hofstaedter F; Hartmann A
    Cancer Immunol Immunother; 2010 Apr; 59(4):529-40. PubMed ID: 19820934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.
    Raffaghello L; Nozza P; Morandi F; Camoriano M; Wang X; Garrè ML; Cama A; Basso G; Ferrone S; Gambini C; Pistoia V
    Cancer Res; 2007 Jun; 67(11):5471-8. PubMed ID: 17545629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
    Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
    Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer.
    Ayshamgul H; Ma H; Ilyar S; Zhang LW; Abulizi A
    Chin Med J (Engl); 2011 Feb; 124(3):341-6. PubMed ID: 21362330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.
    Ferris RL; Hunt JL; Ferrone S
    Immunol Res; 2005; 33(2):113-33. PubMed ID: 16234579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
    Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
    Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.
    Hasim A; Abudula M; Aimiduo R; Ma JQ; Jiao Z; Akula G; Wang T; Abudula A
    PLoS One; 2012; 7(9):e44952. PubMed ID: 23024775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
    Seliger B; Atkins D; Bock M; Ritz U; Ferrone S; Huber C; Störkel S
    Clin Cancer Res; 2003 May; 9(5):1721-7. PubMed ID: 12738726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines.
    Lei WY; Hsiung SC; Wen SH; Hsieh CH; Chen CL; Wallace CG; Chang CC; Liao SK
    J Immunol Res; 2018; 2018():8363265. PubMed ID: 30648121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
    Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
    Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
    J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
    Respa A; Bukur J; Ferrone S; Pawelec G; Zhao Y; Wang E; Marincola FM; Seliger B
    Clin Cancer Res; 2011 May; 17(9):2668-78. PubMed ID: 21248298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma.
    Krishnakumar S; Abhyankar D; Sundaram AL; Pushparaj V; Shanmugam MP; Biswas J
    Clin Cancer Res; 2003 Sep; 9(11):4159-64. PubMed ID: 14519640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
    Campoli M; Ferrone S
    Oncogene; 2008 Oct; 27(45):5869-85. PubMed ID: 18836468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
    Han LY; Fletcher MS; Urbauer DL; Mueller P; Landen CN; Kamat AA; Lin YG; Merritt WM; Spannuth WA; Deavers MT; De Geest K; Gershenson DM; Lutgendorf SK; Ferrone S; Sood AK
    Clin Cancer Res; 2008 Jun; 14(11):3372-9. PubMed ID: 18519766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.